公开(公告)号：US20180036336A1

公开(公告)日：2018-02-08

申请号：US15662706

申请日：2017-07-28

Applicant: Janssen Biotech, Inc.

Inventor： Fei Huang ,  Joshua J. Rusbuldt ,  Aleksandra Rizo

IPC: A61K31/7125 ,  A61K31/496

CPC classification number: A61K31/7125 ,  A61K31/496 ,  A61K31/635 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention relates to a combination treatment for hematological cancers. More specifically; a combination of a telomerase inhibitor and a Bcl-2 inhibitor are useful in treating hematological cancers, including AML. In certain embodiments, the telomerase inhibitor is imetelstat or imetelstat sodium and the Bcl-2 inhibitor is ABT-199.